Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis

Kefei Kang, Kevin D. Cooper, Jon M. Hanifin

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

In a double-blind prospective study, eighteen patients with atopic dermatitis (AD) were treated with thrice-weekly injections of 50 mg thymopoietin pentapeptide (TP-5) or placebo for 6 weeks. Clinical parameters, lymphocyte subsets defined by monoclonal antibodies, and serum IgE were modified. Younger patients (age ¼ 34) responded to TP-5 with much greater improvement in severity scores than TP-5-treated patients of age 〉34 or than placebo-treated patients of either age group (p ¼ 0.05). Both absolute lymphocytes and OKT8+ cytotoxic/suppressor cells were significantly increased (p ¼ 0.05) in the TP-5 group, whereas they were not significantly increased in the placebo group (p>0.05). Conversely, Ia+ cells were significantly increased in the placebo group (p<0.05), but remained the same in the TP-5 group (p>0.05). Serum IgE levels were not significantly altered in either group. Thus, TP-5 had a beneficial clinical effect in AD, especially in younger patients, and increased the reduced OKT8+ cytotoxic/suppressor T cells and prevented an increase of Ia+ cells during pollen season.

Original languageEnglish (US)
Pages (from-to)372-377
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume8
Issue number3
DOIs
StatePublished - Jan 1 1983

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis'. Together they form a unique fingerprint.

  • Cite this